Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 8/20 | 0.50 |
| ▸ | BCHE | P06276 | 4/20 | 0.49 |
| ▸ | LTA4H | P09960 | 7/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14025120 | 0.89 | ACHE (0.49) | ACHEBCHELTA4HCYP2D6NR1H3 | |
| SCHEMBL25495948 | 0.87 | KDM4E (0.56) | ALDH1A1ACHEBCHECYP2D6NR1H3 | |
| SCHEMBL28467850 | 0.83 | CHRNB2 (0.56) | ALDH1A1ACHELTA4HCYP2D6 | |
| SCHEMBL13849587 | 0.82 | LTA4H (0.51) | ALDH1A1ACHEBCHELTA4HCYP2D6 | |
| SCHEMBL7804122 | 0.80 | PLA2G4B (0.60) | ALDH1A1CYP2D6 | |
| SCHEMBL2767522 | 0.80 | SLC7A5 (0.48) | ALDH1A1CYP2D6POLB | |
| SCHEMBL3979830 | 0.79 | SLC7A5 (0.47) | ALDH1A1CYP2D6POLB | |
| SCHEMBL3984588 | 0.79 | SLC7A5 (0.50) | ALDH1A1CYP2D6POLBNR1H3 | |
| SCHEMBL3868045 | 0.79 | SLC7A5 (0.47) | ALDH1A1CYP2D6POLBNR1H3 | |
| SCHEMBL14025014 | 0.79 | SLC7A5 (0.50) | ALDH1A1ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269240-A1 | Novel Adenine Compound | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269240-A1 | Novel Adenine Compound | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269240-A1 | Novel Adenine Compound | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1939199-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269240-A1 | Novel Adenine Compound | ADORA1, ADORA2A, ADORA3 | ALDH1A1 97/4885ACHE 3603/4885BCHE 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.